[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:myd88-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"MYD88 Gene",3,[7,15,21],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06846463","Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+",[11],"Phase 2","RECRUITING","2026-08-26T02:19:13.549512Z","2026-05-05T02:43:28.810232Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT06561347","Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM",[11],"2026-08-26T02:15:21.365312Z","2026-05-05T02:43:27.489259Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT05640102","Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia",[],"2026-08-26T02:16:54.876240Z","2026-05-13T02:55:06.366994Z"]